RHYTHM PHARMACEUTICALS, INC.(RYTM)Stock Analysis

RYTM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RHYTHM PHARMACEUTICALS, INC. (RYTM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RYTM at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,364 of 2,879 stocks — the bottom half of the AI-ranked universe. RYTM scores in the top quartile across revenue growth (92.9). Areas of concern include balance sheet strength (4.3) and profitability (7.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), RHYTHM PHARMACEUTICALS, INC. reports quarterly revenue of $60.1M, net income of $-55.6M, an operating margin of -87.1%. Top institutional holders of RYTM by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock,, BAKER BROS. ADVISORS, based on the most recent SEC filings. RYTM trades on the Nasdaq exchange and files with the SEC under CIK 1649904. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RYTM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RHYTHM PHARMACEUTICALS, INC. directly from SEC EDGAR.